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In patients with detectable virus at the time of liver transplantation, hepatitis C virus (HCV) infection always recurs on the graft, 
and 30% of patients have an aggressive clinical and histologic course with increased morbidity, mortality, and graft loss. Moreover,
in some transplantation patients, recurrent HCV infection leads to an aggressive course of disease known as fibrosing cholestatic 
hepatitis, which is characterized by hepatic decompensation and death. Liver allograft and recipient survival can be substantially 
improved with successful eradication of HCV. Recent advances in direct-acting antiviral agents have revolutionized the manage-
ment of HCV infection, and a number of these agents have shown high sustained virological responses, shorter durations of treat-
ment, and much improved tolerability when compared with previous pegylated interferon based therapies in liver transplant 
settings.
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In the time since hepatitis C virus (HCV) was initially 
discovered, our knowledge of the characteristics of infection 
has advanced rapidly, markedly improving the treatment 
options available to HCV-infected patients. Oral direct-acting 
antiviral agents (DAAs) are modern interferon (IFN)-free 
drug combinations that have dramatically changed the man-
agement of HCV infection, especially in patients with the 
most severe forms of liver disease (decompensated cirrhosis 
and those who are awaiting or have undergone liver trans-
plantation [LT])(1,2). Management of HCV infection in the 
latter patients was challenging in the era of IFN-based the-
rapies. Treatment efﬁcacy was poor and treatment-related 
side effects common; these included hemolytic anemia, pan-
cytopenia, graft rejection, and liver decompensation(3,4). 
New DAA therapies afford sustained (high-level) viro-
logical responses (SVRs) in such patients, with improved 
tolerability, even in those who have previously failed 
IFN-based therapies. Elimination of IFN greatly improves 
the side-effect profile and shortens treatment duration; 
however, the treatment options for such patients remain 
limited. Those undergoing LT require immunosuppressive 
drugs to avoid graft rejection. Such drugs are associated 
with potential drug–drug interactions (DDIs) and metabolic 
burdens newly placed on the engrafted liver. Here, we con-
cisely update the treatment options for HCV infection in 
post-LT patients. 
1. Timing of HCV treatment 
Detectable HCV RNA at the time of LT, is always asso-
ciated with re-infection upon reperfusion(5,6) and is ac-
companied by a rise in the HCV RNA level peaking about 
3∼4 months after operation, together with the development 
of acute hepatitis in most patients(7). Currently, two ther-
apeutic approaches are available. The pre-emptive strategy 
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features treatment early after LT. Alternatively, treatment 
may not commence until recurrent disease is clearly esta-
blished. The potential advantages of early treatment are that 
the HCV RNA levels and liver fibrosis are minimized(8). 
Despite the clear benefits afforded by early treatment, such 
a pre-emptive strategy was historically considered inadvi-
sable because the IFN-based therapies were associated with 
increased rates of acute allograft rejection and de novo au-
toimmune hepatitis. Also, such therapies afforded only 
modest SVR rates in post-LT settings, associated with sig-
nificant adverse side-effects and poor tolerability(3,4). 
However, given the development of potent and safe 
DAA-based therapies, earlier concerns that IFN-related im-
munomodulation was associated with allograft rejection and 
poor tolerance when IFN was employed as an anti-HCV 
therapy after LT is abating. The guidelines of the European 
Association for the Study of the Liver (EASL) and the 
Asian-Pacific Association for the Study of the Liver (APASL) 
recommend that anti-HCV treatment should be initiated 
early after LT, ideally as “early as possible when the pa-
tient is stabilized” (EASL: generally after the first 3 months 
post-transplantation; APASL: 1∼3 months post-transplan-
tation)(9,10). This is because the SVR12 rates are thus di-
minished in patients with advanced liver disease post-LT. It 
is likely that DAA-based therapies, affording better toler-
ability and fewer DDIs than IFN-based therapies, will en-
courage pre-emptive strategies that will become the stand-
ards of care. Also, this is possible even in patients with de-
compensated cirrhosis and fibrosing cholestatic hepatitis 
(FCH; a life-threatening form of recurrent HCV infection) 
in post-LT settings. However, in those, DAA is associated 
with a reduced likelihood of a SVR(11).
2. Treatment options afforded by DAAs in liver 
transplant settings
1) Sofosbuvir and ribavirin 
The NS5B nucleotide inhibitor, sofosbuvir (SOF), has been 
repeatedly shown to yield good SVR rates without any need 
for an additional IFN-based therapy. It is given once daily, 
and has a good safety profile. Also, it has a high barrier 
to resistance, a pan-genotypic antiviral effect. 
The first study to assess the safety and efficacy of an 
IFN-free regimen in HCV-infected post-LT patients pre-
scribed a 24-week combination of SOF and ribavirin (RBV) 
(12). Forty patients with HCV genotypes 1∼4 who were 
at least 6 months after LT were enrolled. The SVR12 rate 
was 70% (28/40); the safety profile was excellent. Of the 
12 patients who experienced virological relapses, 7 suc-
cumbed during follow-up week 2, four during week 4, and 
one during week 12. Although the regimen was suboptimal, 
the results showed that an IFN-free all-oral regimen could 
be used to treat liver transplant recipients as effectively as 
those who did not require transplantation. In a compas-
sionate program, 44 patients with severe HCV recurrences 
following LT, including FCH, were treated with SOF and 
RBV, either with (n=12) or without (n=32) peg-IFN for 24 
weeks(13). The decision to prescribe peg-IFN was left to 
the treating physicians. The reported SVR rate was 60% in 
patients given SOF and RBV and 50% in those taking SOF, 
RBV, and peg-IFN. Due to the severity of HCV at the time 
of treatment initiation, 15 patients died of progressive liver 
disease during treatment. No deaths were attributable to 
SOF or RBV. Liver function tests (e.g., bilirubin level, and 
the international normalized ratio) improved upon 
treatment. Although the trial was small, the data suggest 
that SOF and RBV are safe and effective when used to treat 
HCV infection post-LT. However, the SVR12 rate did not 
attain 90%; the regimen was thus suboptimal.
2) Ledipasvir/sofosbuvir and ribavirin 
Ledipasvir/sofosbuvir (LDV/SOF) is a fixed-dose combi-
nation of ledipasvir, an inhibitor of HCV NS5A, and SOF. 
The SOLAR-1 and SOLAR-2 studies recruited patients with 
end stage liver disease and post LT(14,15). These are phase 
2, prospective randomized multicenter studies prescribing a 
combination of LDV/SOF and RBV for 12 or 24 weeks in 
patients with HCV genotype 1 or 4.
The SOLAR-1 was conducted across 29 clinical sites in 
the United States(14). The RBV doses were weight-based 
for patients without cirrhosis and with Child-Pugh Turcotte 
(CTP) class A. In CTP class B and C patients, RBV was 
initiated at 600 mg/day and increased as tolerated. In total, 
111 patients exhibited fibrosis of grades F0∼F3, whereas 
51, 52, and 9 had CTP class A, B, and C cirrhosis, 
respectively. Among patients without cirrhosis (METAVIR 
grades F0∼F3), the SVR rates were 96% to 98% when 
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LDV/SOF and RBV were given for 12 or 24 weeks. Among 
those with cirrhosis, the SVR rates were 96% for those of 
CTP class A, 85% to 88% for those of class B, and 60% 
to 75% for those of class C, when LDV/SOF and RBV were 
given for 12 or 24 weeks. Six patients with FCH, of whom 
four were treated for 12 weeks and two for 24 weeks, ex-
hibited SVR12 rate of 100%. The response rates in the 12- 
and 24-week groups were similar. Thirteen patients (4%) 
discontinued the regimen prematurely due to adverse 
events; 10 patients died (mainly from complications asso-
ciated with hepatic decompensation). No rejection or renal 
insufficiency was noted, and the blood levels of cyclo-
sporine and tacrolimus did not change significantly.
The SOLAR-2 trial was recently conducted at 34 sites 
across 12 European countries, Australia, Canada, and New 
Zealand; the patient cohort was similar to that of 
SOLAR-1(15). Most patients were infected with HCV of 
genotype 1 (approximately 11% were infected with geno-
type 4); more than 75% of all patients had failed previous 
antiviral therapy. Genotype 1 post-LT patients without cir-
rhosis achieved SVR rates of 93% (42 of 45 patients) and 
100% (44 patients) after 12 and 24 weeks of therapy, 
respectively. Among patients without cirrhosis, the SVR 
rates were 96% to 98% when LDV/SOF and RBV were giv-
en for 12 or 24 weeks. Among patients with cirrhosis, the 
SVR rates were 96% to 100% for those of CTP class A, 95% 
to 100% for those of class B patients, and 50% to 80% for 
those of class C, when LDV/SOF and RBV were given for 
12 or 24 weeks. The results of both the SOLAR-1 and 
SOLAR-2 trials suggest that a short course (12 weeks) of 
LDV/SOF and RBV is probably sufficient for almost all pa-
tients exhibiting genotype 1 HCV recurrence post-LT. 
3) Sofosbuvir and daclatasvir with ribavirin
Daclatasvir (DCV) is a first-in-class HCV NS5A repli-
cation complex inhibitor exhibiting pan-genotypic activity 
and a pharmacokinetic profile allowing once-daily dosing. 
The ALLY-1 phase 3 study assessed the safety and effi-
cacy of SOF and DCV with RBV (initially 600 mg, adjusted 
to 1,000 mg) daily for 12 weeks; the trial contained 53 
Caucasian LT recipients(16). Thirty-one (58%) were in-
fected with HCV of genotype 1a, 10 (19%) with HCV of 
genotype 1b, and 11 (21%) with HCV of genotype 3. Liver 
histology showed that 6 (11%), 10 (19%), 7 (13%), 13 
(25%), and 16 (30%) patients had fibrosis of grades F0, F1, 
F2, F3, and F4, respectively (METAVIR scores). SVR12 
was attained in 50 (94%) patients. In terms of the genotypic 
response, 30 (97%), 9 (90%), and 10 (91%) patients with 
virus of genotypes 1a, 1b, and 3, respectively, achieved 
SVR12. One patient with a genotype 3 infection dis-
continued all medications after 31 days due to headache but 
nonetheless attained SVR12. The study regimen was com-
patible with several concomitant immunosuppressive regi-
mens. No dose adjustments were required and no graft re-
jection was noted. The study showed that the pan-genotypic 
combination was potent, safe, and tolerable in post-LT pa-
tients with HCV infections. The regimen cured most pa-
tients, including those infected with the difficult-to-treat 
genotype 3 HCV. 
The largest observational real-life cohort of transplant re-
cipients is the ongoing French CO23 ANRS CUPILT study, 
which has enrolled 699 patients to date(17). The study as-
sesses the combination of SOF and DCV with or without 
RBV. Of 137 patients assessed, SVR12 has been attained in 
132 (96%), irrespective of the HCV genotype or the dura-
tion of treatment (12 weeks vs. 24 weeks). The CUPILT 
study reports not only high SVR12 rates but also good toler-
ance, no DDIs, and clinical and biochemical improvements. 
4) Ombitasvir/paritritonavir and dasabuvir (Opr＋D) 
with ribavirin
The ombitasvir/paritaprevir/ritonavir and dasabuvir (Opr+D) 
regimen includes ombitasvir, an NS5A inhibitor; par-
itaprevir, an NS3/4A protease inhibitor; ritonavir, a CYP3A 
inhibitor used as a pharmacological booster; and dasabuvir, 
a non-nucleoside NS5B polymerase inhibitor.
CORAL-1 was a phase 2 open-label study of Opr+D with 
RBV over 24 weeks in 34 genotype 1 patients presenting 
with mild fibrosis (METAVIR stages F0∼2)(18); all had 
undergone LT more than 1 year prior to commencing 
Opr+D with RBV. Because of DDIs with calcineurin in-
hibitors (CNIs), the starting dosage of tacrolimus was 0.5 
mg/week or 0.2 mg every other day and the starting dosage 
of cyclosporine was one fifth of the pre-treatment total dai-
ly dose, administered once a day. The use of mTOR in-
hibitors (e.g., rapamycin, everolimus) was prohibited. The 
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Table 1. Recommended HCV treatment for patients in the liver transplantation setting
KASL guideline AASLD/IDSA guideline EASL guideline
HCV genotype 
1 or 4 
- LDV/SOF+R/ R* for 12 weeks 
(R*-decompensated cirrhosis)
- SOF+DCV+R* for 12 weeks
- LDV/SOF for 24 weeks, if contrain-
dicated or intolerant to RBV
- SOF+DCV for 24 weeks, if con-
traindicated or intolerant to RBV
- OPr+D+R for 24 weeks (genotype 1,
Metavir stage F0∼2)
- OPr+R for 24 weeks (genotype 4)
- LDV/SOF+R/ R* for 12 weeks 
(R*-decompensated cirrhosis)
- LDV/SOF for 24 weeks, if contra-
indicated or intolerant to RBV
- SOF+DCV+R* for 12 weeks
- SOF+DCV for 24 weeks, if contra-
indicated or intolerant to RBV
- OPr+D+R for 24 weeks (genotype 
1, Metavir stage F0∼2)
- LDV/SOF+R/ R* for 12 weeks 
(R*-decompensated cirrhosis)
- LDV/SOF for 24 weeks, if contra-
indicated or intolerant to RBV
- SOF+DCV for 24 weeks, if contra-
indicated or intolerant to RBV
HCV genotype 2 - SOF+DCV+R* for 12 weeks
- SOF+DCV for 24 weeks, if contra-
indicated or intolerant to RBV
- SOF+R for 12∼24 weeks
- SOF+DCV+R* for 12 weeks
- SOF+DCV for 24 weeks, if cont-
raindicated or intolerant to RBV
- SOF+R/ R* for 12 weeks 
(R*-decompensated cirrhosis)
- SOF+DCV+R/ R* for 12 weeks 
(R*-decompensated cirrhosis)
- SOF+DCV for 24 weeks, if contra-
indicated or intolerant to RBV
HCV genotype 3 - SOF+DCV+R* for 12 weeks
- SOF+DCV for 24 weeks, if contra-
indicated or intolerant to RBV
- SOF+R for 24 weeks
- SOF+DCV+R* for 12 weeks
- SOF+DCV for 24 weeks, if con-
traindicated or intolerant to RBV
- SOF+R for 24 weeks
- SOF+DCV+R/ R* for 24 weeks 
(R*-decompensated cirrhosis)
Abbreviations: KASL, Korean Association for the Study of the Liver; AASLD/IDSA, American Association for the Study of Liver 
Diseases/Infectious Diseases Society of America; EASL, European Association for the Study of the Liver; SOF, sofosbuvir; LDV, ledipasvir; 
DCV, daclatasvir; R, weight-based ribavirin; R*, ribavirin started from 600 mg/d; OPr, ombitasvir/paritaprevir/ritonavir; D, dasabuvir.
Adapted from reference(9,19,20).
dosages of CNIs were adjusted during treatment by refer-
ence to the trough levels. SVRs were attained in 97% 
(33/34) of patients. One patient relapsed on post-treatment 
Day 3. One patient ceased treatment due to an adverse event 
but nonetheless attained SVR. Of all patients, 17% (5/29) 
exhibited tacrolimus levels ＞15 ng/mL during treatment 
(mostly attributable to dosing errors) and, in 28% (8/29), 
one or more measured tacrolimus levels lay below the refer-
ence range after treatment ceased. No rejection was noted. 
Opr+D with RBV did not change the trough levels of either 
tacrolimus or cyclosporine. Although Opr+D regimen is 
FDA-approved for use in post-transplant patients, there is 
the greater likelihood of DDIs with CNIs. Also, safety and 
efficacy data are lacking for patients with fibrosis METAVIR 
scores ＞F2. 
These Phase 2/3 and real-world studies have influenced 
the Korean and international HCV treatment guidelines, 
which currently recommend IFN-free all-oral DAA regi-
mens for all post-LT patients with HCV infections (Table 
1)(9,19,20).
3. Drug-drug Interactions 
Before initiation of any DAA, potential DDIs must be 
considered, including those attributable to both prescription 
and over-the counter pharmaceuticals. Furthermore, DDIs 
between DAAs and immunosuppressive drugs, principally 
CNIs, remain of concern when DAA-based therapies are 
prescribed. Also, chronic exposure to CNIs may cause pro-
gressive declines in renal function, thereby reducing RBV 
clearance, which may in turn increase the frequency and 
severity of RBV-associated hemolytic anemia.
Cyclosporine and tacrolimus alter the concentrations of 
DCV and SOF somewhat, but the changes are not clinically 
significant(9,21). Although the maximal concentration and 
exposure to SOF increase 2.5- and 4.5-fold, respectively, 
when SOF is given with cyclosporine, the increases in SOF 
concentration and SOF metabolites are not associated with 
any apparent toxicity. DCV affects neither cyclosporine nor 
tacrolimus levels, although modest increases in DCV ex-
posure were observed. Concomitant use of SOF, LDV, or 
DCV with either CNI is considered safe. Also, no SOF, 
LDV, or DCV dose reductions are recommended for patients 
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with hepatic impairment. However, close monitoring of im-
munosuppressant trough levels before, during, and after 
DAA therapy is essential. In the CUPILT study, the dose 
of one immunosuppressive drug had to be changed in 59% 
of 130 patients treated with SOF and DCV after LT(17). 
Opr+D increases the serum cyclosporine and tacrolimus lev-
els; dose adjustments are required(9,18-21). More data are 
needed on the concomitant use of mTOR inhibitors(e.g., ra-
pamycin, everolimus) and the new DAAs.
CONCLUSION
The rapid advances in hepatitis C treatment have led to 
a paradigm change. Recurrent HCV infection following LT 
can accelerate allograft injury that is difficult to treat with 
peg-IFN-based regimens. Such regimens may be poorly tol-
erated, afford only modest efficacy, and may interact neg-
atively with immunosuppressive agents. IFN-free all-oral 
DAA regimens have consistently yielded high SVR rates and 
better side-effect profiles. Also, treatment courses can be 
short. Appropriate treatment of HCV infection in the LT 
setting will minimize graft failure, morbidity, and mortality.
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